Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases.

Published

Journal Article

BACKGROUND: Early experiments using ligand-binding assays demonstrated the presence of estrogen receptor (ER) in fibromatoses. These findings were not confirmed by later studies using immunohistochemical analysis. METHODS: To verify the expression of ERs in fibromatosis as well as to clarify the inconsistency between radioligand and early immunohistochemical studies, the authors examined a series of 40 extraabdominal fibromatoses using antibodies raised against ERbeta. RESULTS: All 40 cases of extraabdominal fibromatosis were at least focally positive for ERbeta. Thirty-three of 40 (83%) displayed 3+ (>50%) expression, 5 of 40 (12%) were 2+ (11-50%), and 2 of 40 (5%) cases showed 1+ (<10%) expression. All cases were negative for ERalpha. CONCLUSIONS: Although extraabdominal fibromatosis does not express ERalpha, there appears to be nearly uniform expression of ERbeta. This finding clarifies discrepancies in the literature regarding estrogen expression in fibromatosis, and provides a biological mechanism for the action of antiestrogenic compounds in the treatment of fibromatosis. Estrogen antagonists may have a role in the treatment of refractory or recurrent extraabdominal fibromatoses.

Full Text

Duke Authors

Cited Authors

  • Deyrup, AT; Tretiakova, M; Montag, AG

Published Date

  • January 1, 2006

Published In

Volume / Issue

  • 106 / 1

Start / End Page

  • 208 - 213

PubMed ID

  • 16333857

Pubmed Central ID

  • 16333857

International Standard Serial Number (ISSN)

  • 0008-543X

Digital Object Identifier (DOI)

  • 10.1002/cncr.21553

Language

  • eng

Conference Location

  • United States